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Since the introduction of active immunisation against tetanus in 1923, there has been a dramatic decline in cases 
of tetanus all over the world. However, cases of tetanus are still being reported in developing and developed 
economies; with more cases reported from Africa than from Europe. The three planks in the management of 
tetanus are the elimination of toxin production, neutralisation of unbound toxin and control of spasms. In this 
report of a fifteen-year old Nigerian female patient with Ablett II tetanus, elimination of toxin production was by 
the combination of metronidazole and the glutamate transporter I (GLT I) enhancer, ceftriaxone. Neutralisation 
of unbound toxin was by the use of anti-tetanus serum due to the non-availability of human tetanus immune 
globulin. Control of spasms was mainly by the use of the GABAergic-enhancing drugs diazepam and sodium 
valproate combined with the use of the anti-excitotoxics magnesium sulphate and ketamine. The introduction of 
valproate hastened the disappearance of opisthotonus and residual rigidity and deserves to be added to drug 
combination regimens for tetanus. 
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1.0  Introduction 
Tetanus is characterised by the acute onset of hypertonia and muscle spasms which begin initially in the jaw 
muscles. This is the cause of the trismus (lockjaw) which may be an early diagnostic hall-mark of tetanus. This 
lockjaw is due to spasms of the masseter muscles. Spasms progressively extend to the facial muscles causing the 
typical facial expression, ‘risus sardonicus’, and muscles of swallowing causing dysphagia. Generalised muscle 
rigidity and tonic contractions of agonist and antagonist muscles cause opisthotonus. During this, patients have 
an intact sensorium and feel severe pain (emedicine.medscape.com). The spasms can cause fractures and 
respiratory failure. As the disease progresses, mild stimuli may trigger generalised tetanic seizure-like activity 




Despite the availability of passive immunisation since 1893 and an effective active vaccination since 1923, 
tetanus remains a major health problem in the developing world and is still encountered in the developed world. 
There are between 800,000 and I million deaths due to tetanus each year, of which about 400,000 are due to 
neonatal tetanus. Eighty percent of these deaths occur in Africa and South-East Asia and tetanus remains 
endemic in 90 countries worldwide (Farrar et al. 2000) in spite of the WHO’s efforts, such as the Maternal and 
Neonatal Tetanus Elimination Initiative (MNTE) (Owusu-Darko et al. 2012). It has now been realised that it is 
not possible to eradicate the disease tetanus, due to its nature (WHO.int/immunisation, monitoring/MNTE 
Strategic plan) and so the goal is to eliminate maternal and neonatal tetanus (MNT) as a public health problem as 
called for by the 42
nd
 World Health Assembly in 1989 and endorsed by the World Summit for Children in 1990 
and later reinforced by the relaunch of the MNTE initiative in 1999. The year 2015 is the global target by WHO 
for reaching MNTE in all countries. 
 
1.2 Microbiology 
Tetanus is caused by a Gram-positive bacillus, Clostridium tetani, a natural habitat of soil which can also be 
isolated from stools of domestic animals and humans. It is a motile, spore-forming obligate anaerobe. The spore 
is incompletely destroyed by boiling but eliminated by autoclaving at I atmosphere pressure and 120ᵒC for 15 
min. It is rarely cultured, as the diagnosis of tetanus is clinical (Cook et al. 2001). Clostridium tetani produces its 
clinical effects via a powerful exotoxin, tetanospasmin. The DNA for this toxin is contained in a plasmid which 
is not present in all strains of clostridia. 
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Binding of this spasmogenic toxin to neurons is irreversible and nerve function can only be returned by the 
growth of new terminals and synapses (Farrar et al. 2000). And because anti-tetanus serum or tetanus immune 
globulin can neutralise toxin in circulation but not toxin bound to neurons, patients with tetanus are likely be in 
critical care for the 2-3 weeks it may take for the toxin bound to neurons to be depleted. 
Extent of adequate antitetanus immunity in the adult population tends to wane (Bleck 1991) and physicians 
become less comfortable with tetanus diagnosis and management as new cases drop (Schon et al. 1994) 




The tetanus bacillus secretes two toxins, tetanospasmin and tetanolysin. Tetanolysin optimises the conditions for 
bacterial multiplication by its haemolysins. Tetanospasmin leads to the clinical syndrome of tetanus (Rodrigo et 
al. 2014). 
Tetanospasmin is a two-chain polypeptide of 150,000 Da which is initially inactive. The heavy chain 
(100,000 Da) and the light chain (50,000 Da) are linked by a protease sensitive loop that is cleaved by tissue 
proteases leaving a disulphide bridge linking the two chains. Binding to the polysialoganglioside receptor is by 
means of the Hc fragment of the heavy or B chain.  It is recently reported that tetanospasmin may be more 
specific for the glycosylphosphatidylinositol (GPI)-anchored protein receptor (Munro et al. 2001). The light or 
A-chain, a zinc endopeptidase attacks the vesicle-associated membrane protein (VAMP), synaptobrevin and 
selectively acts to prevent inhibitory neurotransmitter release from spinal cord interneurons (Kanda and Takano 
1983), leaving the alpha-motoneurones with unopposed excitatory actions. Cleavage of synaptobrevin affects the 
stability of the soluble N-ethylmaleimide sensitive fusion attachment protein receptor complex (SNARE) core by 
restricting it from entering the low energy conformation which is the target of N-ethylmaleimide sensitive fusion 
(NSF) protein binding (Pellegrini et al. 1995). 
1.3.1 Mechanism of tetanospasmin: 6 steps 
a): specific binding to the peripheral neurons 
b): selective retrograde transsynaptic transfer subsequent to its retrograde axonal transport to the CNS inhibitory 
interneurons by means of the molecular motors, dyneins (Schwab et al. 1979; Lalli et al. 2003) that move on 
microtubules to effect cargo transport. 
c): transcytosis from the axon into the inhibitory neurons presynaptic nerve endings 
d): temperature and acidic pH mediated traslocation of the light chain into the cytosol 
e): reduction of the disulphide bond between the light and heavy chains (mediated by the HN  fragment of the B 
chain); thus freeing the light chain for attack on synaptobrevin. 
f): cleavage of synaptobrevin (Schiavo et al. 1992) and subsequent differential blockade of release of the 
inhibitory neurotransmitters, glycine and gamma-amino-butyric acid (GABA). 
Further retrograde intraneural transport may occur in severe cases with toxin spreading to the 
brainstem and midbrain (Cook et al. 2001).  Blood-brain-barrier (BBB) normally prevents direct entry of toxin to 
the CNS. Tetanospasmin has a convulsant effect in animal models (Altenmuller et al. 2013; Anderson et al. 
1997). 
Hyperglutamatergic excitotoxicity is implicated in the mechanisms of neuronal degeneration and 
neuronal loss produced by intrahippocampal tetanus toxin in rat (Baggeta and Nistico 1992). Intrahippocampal 
tetanus toxin produces generalised convulsions and neurodegeneration antagonised by NMDA receptor blockers 
(Bowery et al. 1992). 
 
1.4 Clinical Features 
Tetanus usually follows a recognised injury (Cook et al. 2001). Contamination of wound with soil, manure, or 
rusty metal can lead to tetanus. Tetanus can complicate burns, ulcers, gangrene, necrotic snakebites, middle ear 
infections, septic abortion, childbirth, intramuscular injections and surgery. In 15-25% of patients, there is no 
evidence of a recent wound or there may be a wound not considered serious enough to seek medical treatment 
(Edmondson and Flowers 1979). 
There is a clinical triad of rigidity, muscle spasms and, if severe, autonomic dysfunction. Neck 
stiffness, sore throat and difficulty opening the mouth are often early symptoms (Alfery and Rauscher 1979). 
Interneuronal dysfunction with hyperactivity of gamma-motoneurons contributes to the rigidity in an early stage 
of the disease (Bratzlavsky and Vander-Eecken 1980) 
Masseter spasm causes trismus, an early diagnostic feature of tetanus. Spasms of facial muscles cause 
risus sardonicus. Spasms of muscles of swallowing cause dysphagia. Rigidity of the neck muscles leads to 
retraction of the head while truncal rigidity may lead to opisthotonus and respiratory difficulty with decreased 
chest wall compliance. 
These spasms may be spontaneous or triggered by touch, visual, auditory or emotional stimuli. Spasms 
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may be almost continual leading to respiratory failure (Kokal et al. 1984). Pharyngeal spasms are often followed 
by laryngeal spasms and are associated with aspiration and life-threatening acute airways obstruction. 
In generalised tetanus, muscles throughout the body are affected. This is the commonest form of 
tetanus. With lower toxin loads and peripheral injuries, local tetanus is seen. Cephalic tetanus results when 
localised tetanus from a head wound affects the cranial nerves III, IV, VI, VII and XII but especially VII (facial 
nerve) and paralysis predominates (Seo et al. 2012). Cephalic tetanus may progress to generalised tetanus and 
mortality is high. Tetanus neonatorum causes more than 50% of deaths from tetanus worldwide (Galazka and 
Gasse 1995). Before the introduction of artificial ventilation, many patients with severe tetanus died from acute 
respiratory failure (Trujillo et al. 1987). 
Severe tetanus is associated with marked autonomic instability with periods of severe hypertension and 
tachycardia alternating with periods of profound hypotension, bradycardia or recurrent cardiac arrest. During 
these ‘storms’, plasma catecholamine levels may be raised up to 10-fold, similar to levels seen in 
phaeochromocytoma (Domenighetti et al. 1984). This hyperadrenergic syndrome that occurs in severe tetanus is 
characterised by hypertension, tachycardia and increased systemic arteriolar resistance and is responsive to the 
combined beta- and alpha-adrenergic receptor blocker, labetalol (Domenighetti et al. 1984; Alagbe-Briggs and 
Tinubu 2012); and may be responsible for the unexpected cardiac arrests which is the commonest cause of 
deaths of patients in intensive care under artificial ventilation (Trujillo et al. 1987). Neuronal hyperactivity rather 
than adrenal medullary hyperactivity appears to predominate (Toothill et al. 1970). 
 
1.5 Natural history 
The incubation period is the time from injury to first symptoms and averages 7-10 days with a range of 1-60 
days. The onset time is time of first symptoms to first spasm and varies between 1-7 days. Shorter incubation and 
onset times are associated with more severe illness. Spasms reduce after 2-3 weeks but stiffness may persist 
considerably longer. Recovery from tetanus occurs because of re-growth of axon terminals (Bleck 1987; 
Dunchen and Tonge 1973) and by toxin destruction (Dance and Lipman 1994). 
 
1.6 Severity grading 
The grading system reported by Ablett is most widely used (Phillips 1967): 
 
Table 1: ABLETT CLASSIFICATION OF SEVERITY OF TETANUS 
Grade: Clinical features 
I Mild: mild to moderate trismus; general spasticity; no respiratory 
embarrassment; no spasms; little or no dysphagia. 
II Moderate: moderate trismus; well-marked rigidity; mild to moderate but short 
spasms; moderate respiratory embarrassment with an increased respiratory 
rate greater than 30; mild dysphagia. 
III Severe: severe trismus; generalized spasticity; reflex prolonged spasms; 
increased respiratory rate greater than 40; apnoeic spells; severe 
dysphagia; tachycardia greater than 120. 
IV Very severe: grade III and violent autonomic disturbances involving the 
cardiovascular system. Severe hypertension and tachycardia alternating 
with relative hypotension and bradycardia, either of which may be 
persistent. 
 
1.7 Systemic effects of tetanus 
Severe uncomplicated tetanus is marked by a hyperkinetic circulation (James and Manson 1985). Apart from the 
effects on the circulatory system in severe tetanus, the restrictive defect as a result of spasms of chest, 
diaphragmatic and abdominal musculatures impact negatively on respiratory physiology. 
Hypoxia is a uniform finding in moderate or severe tetanus even when the chest wall is radiologically clear 
(Udwadia 1994). And acute respiratory distress syndrome may occur as a specific complication of tetanus. 
In mild tetanus, renal function is preserved. In severe disease, reduced glomerular filtration rate and impaired 
renal tubular function are frequent. Contributory causes of renal failure include dehydration, sepsis and 
rhabdomyolysis (Seedat et al. 1981) and alterations in renal blood flow secondary to catecholamine surges. 
 
1.8 Prognosis 
Prognosis of tetanus is dependent on: 
a) incubation period 
b) time from spore inoculation to first symptom 
c) time from first symptom to first tetanic spasm (onset) 
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Shorter intervals indicate more severe disease and a poorer prognosis. 
 
Table II Prognostic Scoring in Tetanus:                           Dakar Score 
Prognostic factor            Score (1)                                    Score (0) 
Incubation period            < 7 days                                         > 7 days or unknown 
Period of onset               < 2 days                                          > 2 days 
Entering site                   umbilicus, burn, uterine,                 All others plus unknown 
                                        open fracture, surgical wound,  
                                        IM injection                                     
Spasms                            Present                                           Absent 
Fever                 > 38.4ᵒC                                    < 38.4ᵒC 
Tachycardia                    Adults > 120 beats/min                 Adults < 120 beats/min 
                                        Neonates > 150 beats/min            Neonates < 150 
                                                                                                beats/min 
Table II: The Dakar Score is a prognostic scoring system proposed by a team from Dakar, Senegal in 
1975 which can be established after the third day following the first clinical signs. The prognosis is bleaker as 
the clinical score increases (Ogunrin 2009) 
 
Table III         Predictive value of Dakar Score 
0-1:    mild tetanus,   mortality below 15% 
2-3:    moderate tetanus,  mortality 10-20% 
4 :      severe tetanus,   mortality 20-40% 
5 or 6:    very severe tetanus,  mortality above 50% 
 
1.9 Complications of tetanus 
These include asphyxia, sudden cardiac death, nosocomial infection, fractures of long bones, aspiration 
pneumonia, peripheral thromboembolism, hypertension and arrhythmias. Others are paralytic ileus, pressure 
sores, urinary retention, stress ulcers, coma, nerve paralysis and flexion contractures. 
 
1.10 Differential diagnosis of tetanus 
1) strychnine poisoning 
2) dental infection causing trismus 
3) local oral infection causing trismus 
4) hysteria (especially nowadays disease is not common) 
5) neoplasm 
6) malignant hyperthermia 
7) stimulant use 
8) intracranial haemorrhage 
9) dystonic drug reaction from neuroleptic use 
10)  acute abdomen 
11) seizure disorder 




2.0  Management 
The management of tetanus rests on three planks: a) prevention of further toxin production and release, b) 
neutralisation of unbound toxin, c) control of rigidity and spasms. 
 
2.1  Prevention of further toxin production and release 
Where present, obvious wounds should be surgically debrided (Owusu-Darko et al. 2012) after patients have 
been started on antibiotics. Metronidazole is the antibiotic of choice (Ahmadsyah and Salim 1985) in preference 
to penicillin which is a GABA antagonist and pro-convulsant. Other antibiotics that may be used against this 
anaerobic Gram-positive bacillus include doxycycline, erythromycin, chloramphenicol and vancomycin. It is 
now known that selected β-lactam antibiotics, to which Clostridia tetani is sensitive to (www.globalrph.com), 
such as ceftriaxone may offer neuroprotection by increasing glutamate transporter I or excitatory amino acid 
transporter 2 (EAAT 2) expression (Rothstein et al. 2005). 
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2.2  Neutralisation of unbound toxin 
Use of human tetanus immune globulin (5,000-8,000 i.u) is safer and more effective the anti-tetanus serum (500-
1,000 i.u/kg) in neutralisation of unbound toxin and both can be given intra-thecally, intravenously or intra-
muscularly (Farrar et al. 2000). Human tetanus immune globulin may not be readily available in emerging 
economies. The combination of intra-thecal anti-tetanus serum and parenteral betamethasone have been found 
beneficial (Thomas et al. 1982). Higher doses of anti-tetanus serum may be associated with hypersensitivity 
reactions. 
 
2.3  Control of rigidity and spasms 
The ideal therapeutic regimen should abolish spasmodic activity without causing oversedation and 
hypoventilation (Ogunrin 2009). Drug combinations may be a method to reduce toxicity as it allows doses of 
individual drugs to be reduced. 
2.3.1  Use of drugs that enhance GABAergic neurotransmission 
In tetanus, there is antagonism of release of the main inhibitory neurotransmitter in the central nervous system, 
GABA. Therefore, drugs that enhance GABAergic neurotransmission may be indispensable for the management 
of tetanus, especially Ablett I and II: 
a) The benzodiazepines: These have emerged as the mainstay of symptomatic therapy for tetanus. 
Diazepam, which is easily available, is a prototype of the benzodiazepines. Doses of diazepam (3-8 
mg/kg/day) required to adequately control spasms are associated with respiratory depression, coma and 
medullary depression. Therefore, its combination with other drugs such as the neuroleptic, 
chlorpromazine may be mandatory. Diazepam enhances GABAergic neurotransmission by increasing 
the frequency of channel opening (Twyman et al. 1989) to cause sedation. 
b) Valproate: Animal experimentations have revealed a significant role for the anti-epileptic valproate in 
attenuation or abrogation of spasms due to tetanus toxin (Altenmuller et al. 2013; Foca et al. 1984). 
Moreover, valproate may help with the cognitive decline after tetanus (Anlar et al. 1989). Valproate 
inhibits GABA-aminotransferase, thereby inhibiting GABA breakdown. 
c) Pyridoxine: Pyridoxine is a coenzyme with glutamic decarboxylase in production of GABA from 
glutamic acid and has been tried (Godel 1982) and found to decrease mortality and spasms in neonatal 
tetanus. 
d) Baclofen: The GABA B agonist may be used in severe tetanus by intra-thecal administration in 
artificially ventilated patients (Rodrigo et al. 2014). Facilities for prolonged periods of ventilation are 
limited in many developing countries where tetanus may still pose a major threat (Rodrigo et al. 2014). 
2.3.2 Use of anti-excitotoxics in tetanus 
Tetanus may be a hyperglutamatergic state that may respond to anti-excitotoxics (Bowery et al. 1992): 
a) Magnesium sulphate: Magnesium sulphate has been used both in ventilated patients to reduce 
autonomic disturbance and in non-ventilated patients to control spasms. Magnesium sulphate, by 
lowering intracellular and serum calcium, reduces Ca
2+
-induced excitotoxicity and muscular 
contractions. In overdose, it causes sedation or even paralysis. Given for 7 days, it reduces 
incidence of sympathetic over-activity (Thwaites et al. 2006) and autonomic instability (Rodrigo et 
al. 2014). It is usually given as a loading dose of 75 mg/kg or 5 gms., then infused at a rate of 2-3 
gm/hr (Hinfey  2014). It has been found adequate in Ablett II where it controls the spasms and 
allows fluid intake, without need for heavy sedation and artificial ventilation, useful attributes 
especially in poor-resource settings. It helps to avoid the risks of prolonged periods of intubation 
and ventilation which includes ventilator-associated pneumonia, tracheal stenosis, difficulty in 
weaning and adult respiratory distress syndrome. 
b) Ketamine: Ketamine, a dissociative anaesthetic agent, remarkably inhibits calcium currents (Tan et 
al. 2010; Sun et al. 2004; Hatekeyama et al. 2001) to provide neuroprotection and muscle 
relaxation in tetanus (Obanor et al. 2008). 
c) Alpha2-adrenoceptor agonists: Clonidine and dexmedetomidine are examples of α2-adrenoceptor 
agonists that inhibit Ca
2+
-mediated excitotoxicity to provide neuroprotection and muscle relaxation 
(Ma et al. 2005) and have been used in tetanus care for their sedative effects (Cook et al. 2001). 
d) Dantrolene: The ryanodine receptor blocker, dantrolene, protects motoneurons against Ca
2+
-
mediated excitotoxicity (Haastert et al. 2006) mediated by AMPA receptors and can cause muscle 
relaxation. Its use may obviate the need for neuromuscular blockers in severe tetanus. 
2.3.4   Use of neuromuscular blockers in severe tetanus 
Neuromuscular blockers such as pancuronium (Dance and Lipman 1994) may be deployed when GABAergic 
agents and anti-excitotoxics fail to control the spasms. Their use is combined with intermittent positive pressure 
ventilation and is expensive. 
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3.0   Case Report 
A fifteen-year old Nigerian female, residing in Ekpoma, presented in Oseghale Oriaifo Medical Centre, 
Idumebo-Ekpoma on 15
th
 of January, 2015 with a diagnosis of hysteria from another clinic which had not 
responded to usual medications. On examination, she was not pale and not dehydrated. Respiratory rate was 
regular, 28/min and blood pressure was 110/70 mm.Hg, regular pulse at 98 beats/min. There was an injury on 
left great toe which was sustained in the farm. According to relations, injury had been there for up to 2 weeks. 
There was moderate trismus, neck stiffness and board-like rigidity of the abdomen. There was moderate 
dysphagia and moderate spasms on provocation. There were no apnoeic spells. Diagnosis of Ablett II tetanus 
was made.  Dakar prognostic score was put at 2 since there was a surgical wound and there were spasms already. 
Incubation period was more than 2 weeks and time of onset was more than 2 days. 
 
3.1   Pharmacologic treatment 
Metronidazole (200 mg in infusion fluid every 8 hours) and ceftriaxone (one gram intravenously every 12 hours) 
were given to accelerate wound healing and stop production of toxin. The wound healed completely after 3 days. 
Anti-tetanus serum (ATS) was given intra-muscularly in divided doses to counter the toxin in circulation. Up to 
26, 000 units of ATS was given. Prophylactic tetanus toxoid injection was started. 
Sedation was started with low doses of intravenous diazepam (20 mg every 6 hours) and intravenous 
chlorpromazine (100 mg every 6 hours). This proved inadequate as spasms got prolonged and the dreaded 
opisthotonus ensued. Low dose of magnesium sulphate was commenced starting with a bolus of 5 grams and 
then 1 gram in intravenous fluid hourly. This was reduced to 5 grams intramuscularly after ketamine was added 
to the drug combination therapy. Institution of magnesium sulphate therapy lessened the severity of the trismus, 
allowing the patient to take sips of fluid orally after 36 hours. Ketamine was given in doses of 20 mg 
intravenously every 6 hours. 
Above proved inadequate to stop or reduce the opisthotonus. Sodium valproate was then added to the 
drug combination therapy as a loading dose of 20 mg/kg in infusion fluid; and continued for another 24 hours at 
15 mg/kg in divided doses in infusion fluid. This was then changed to valproate tablets which was continued at a 
dose of 500 mg twice daily given after grinding. The addition of valproate stopped the opisthotonus and also 
allowed patient to swallow better. Pyridoxine tablets was also given at a dose of 100 mg/day. With this 
combination therapy, spasms and the board-like rigidity of the abdomen stopped after 11 days of admission 
when swallowing got freer but residual rigidity continued for another week. Injections were tapered off after 3 
weeks. 
Patient was discharged after 3 weeks in hospital, and when she was seen at 4 weeks for her second 
tetanus toxoid injection, she was able to be on a motor-bike! 
 
4.0 Discussion 
Present report shows that there may be delay in diagnosis of tetanus now it has become a rare disease in Nigeria 
since the advent of active immunisation. This is similar to what may obtain elsewhere (Bleck 1991; Schon et al. 
1994). Medical practitioners should be aware that a differential diagnosis of tetanus is hysterical conversion and 
acute abdomen! 
The addition of ceftriaxone to metronidazole is synergistic and could have accelerated the attenuation 
of toxin production, and wound healing in this patient. Ceftriaxone is anti-excitotoxic and increases glutamate 
uptake by effect on glutamate transporter-I and cysteine/glutamate exchanger transporter (Zeng et al. 2010; 
Goodrich et al. 2013; Alhaddad and Sujan 2014). By its anti-depressant effects (Mineur et al. 2007), it stands to 
aid in the upregulation of GABAergic mechanisms and eventual patient recovery. Additionally, the institution of 
metronidazole + ceftriaxone combination is in good stead to prevent sepsis and pneumonia in tetanus patients. 
This is the first report of the use of ceftriaxone to aid recovery in tetanus patients. 
The combination therapy of sedatives and anti-excitotoxics in this patient allowed doses of individual 
drugs to be reduced, thus minimizing toxicity. Magnesium sulphate is known to prevent autonomic instability in 
tetanus patients (Rodrigo et al. 2014). In this patient, there was no autonomic instability.  Rodrigo et al (2014) 
also noted that magnesium sulphate allowed the earlier institution of oral intake and obviated the need for 
nutritional support especially in Ablett II tetanus. Our report agrees with this observation. Low-dose magnesium 
sulphate has also been reported to be suitable for management of eclampsia where excitotoxicity is coupled to 
seizures (Shilva et al. 2007). The anti-excitotoxic and anti-depressant, ketamine, is reported to help suppress the 
spasms of tetanus when other drugs prove inadequate (Obanor et al. 2008). Ketamine is known to suppress 
calcium currents (Tan et al. 2010). 
The anti-epileptic, valproate, enhances GABA neurogenesis (Laeng et al. 2004) and GABAergic 
neurotransmission, an attribute that already makes it useful for generalised convulsive status epilepticus (Chen et 
al. 2011). Moreover, valproate attenuates Ca
2+
-mediated excitotoxicity (Chen et al. 2007), a property that could 
make it synergise with magnesium sulphate to help quench excitotoxicity coupled to seizures as happens in 
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tetanus. A beneficial effect of this combination has previously been reported (Barbosa et al. 2011). Valproate 
does not easily cause respiratory depression and hypotension when compared to diazepam (Chen et al. 2011). 
The addition of valproate to the combination therapy in this patient hastened the disappearance of opisthotonus 
and accelerated recovery of deglutition. Valproate has previously been demonstrated in animal models to 
enhance survival from tetanus seizures (Altenmuller et al. 2013; Foca et al. 1984). We report here for the first 
time the safety and tolerability of adjunctive low-dose valproate in tetanus; a drug that could also attenuate the 
cognitive decline after tetanus (Hashimoto et al. 2002; Laeng et al. 2004; Tsai et al. 2010; Chiu et al. 2013). 
 
5.0  Conclusion 
In conclusion, adjunctive use of low-dose valproate appears to synergise with low-dose magnesium sulphate, 
diazepam, chlorpromazine and ketamine in the management of Ablett II tetanus in a young Nigerian girl. Also, 
the combination of metronidazole and ceftriaxone may synergise potently in accelerating healing of and stopping 
toxin production from the infected wounds of tetanus patients. 
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